Clinical trials
Phase 3 Back Pain trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
54 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 7 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 39 |
| Unknown status | 6 |
| Recruiting | 3 |
| Terminated | 3 |
| Withdrawn | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| BioDelivery Sciences International | 4 |
| Eli Lilly and Company | 3 |
| Apurano Pharmaceuticals GmbH | 2 |
| EMS | 2 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2 |
| Laboratorios Silanes S.A. de C.V. | 2 |
| Ortho-McNeil Janssen Scientific Affairs, LLC | 2 |
| Purdue Pharma LP | 2 |
| University of Colorado, Denver | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Back Pain | 54 |
| Low Back Pain | 19 |
| Pain | 16 |
| Chronic Pain | 13 |
| Neck Pain | 9 |
| Osteoarthritis | 8 |
| Spasm | 4 |
| Neuralgia, Postherpetic | 3 |
| Spinal Fractures | 3 |
| Acute Pain | 2 |
Trials
Showing 1 to 25 of 54. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.